Muhlenkamp & Co Inc Buys Bristol-Myers Squibb Company, Dow Inc, Lennar Corp, Sells Celgene Corp, Gilead Sciences Inc, Cognizant Technology Solutions Corp

• New Purchases: BMY, LEN, TEN, RUSHB,
• Added Positions: DOW, CVS, PKW, JAZZ, AMLP, AVGO, GMLP, CI,
• Reduced Positions: GILD, CTSH, CCJ, MSFT, AAPL, ADS, PFE,
• Sold Out: CELG, CTVA,

For the details of Ronald Muhlenkamp's stock buys and sells, go to https://www.gurufocus.com/guru/ronald+muhlenkamp/current-portfolio/portfolio

1. Apple Inc (AAPL) - 58,874 shares, 7.56% of the total portfolio. Shares reduced by 6.43%
2. Microsoft Corp (MSFT) - 101,622 shares, 7.00% of the total portfolio. Shares reduced by 8.22%
3. SPDR Gold Trust (GLD) - 83,028 shares, 5.19% of the total portfolio. Shares added by 0.08%
4. Rush Enterprises Inc (RUSHA) - 249,989 shares, 5.08% of the total portfolio. Shares added by 0.04%
5. Microchip Technology Inc (MCHP) - 95,065 shares, 4.35% of the total portfolio. Shares reduced by 0.06%

Muhlenkamp & Co Inc initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $49.21 and $64.19, with an estimated average price of $57.47. The stock is now traded at around $65.17. The impact to a portfolio due to this purchase was 3.46%. The holding were 123,223 shares as of .

Muhlenkamp & Co Inc initiated holding in Lennar Corp. The purchase prices were between $55.24 and $61.97, with an estimated average price of $58.95. The stock is now traded at around $71.03. The impact to a portfolio due to this purchase was 2.24%. The holding were 92,060 shares as of .

Muhlenkamp & Co Inc initiated holding in Tenneco Inc. The purchase prices were between $10.09 and $15.57, with an estimated average price of $13.12. The stock is now traded at around $10.87. The impact to a portfolio due to this purchase was 2.14%. The holding were 373,957 shares as of .

Muhlenkamp & Co Inc initiated holding in Rush Enterprises Inc. The purchase prices were between $37.19 and $48.11, with an estimated average price of $43.76. The stock is now traded at around $44.35. The impact to a portfolio due to this purchase was 0.09%. The holding were 4,430 shares as of .

Muhlenkamp & Co Inc added to a holding in Dow Inc by 295.35%. The purchase prices were between $43.85 and $55.99, with an estimated average price of $51.84. The stock is now traded at around $48.76. The impact to a portfolio due to this purchase was 2.66%. The holding were 148,841 shares as of .

Muhlenkamp & Co Inc added to a holding in CVS Health Corp by 52.09%. The purchase prices were between $60.38 and $76.58, with an estimated average price of $70.48. The stock is now traded at around $71.94. The impact to a portfolio due to this purchase was 1.18%. The holding were 106,514 shares as of .

Muhlenkamp & Co Inc added to a holding in Invesco BuyBack Achievers ETF by 104.44%. The purchase prices were between $60.32 and $69.3, with an estimated average price of $66.01. The stock is now traded at around $69.31. The impact to a portfolio due to this purchase was 0.99%. The holding were 64,195 shares as of .

Muhlenkamp & Co Inc added to a holding in Jazz Pharmaceuticals PLC by 36.93%. The purchase prices were between $117.65 and $153.73, with an estimated average price of $136.72. The stock is now traded at around $135.50. The impact to a portfolio due to this purchase was 0.87%. The holding were 49,626 shares as of .

Muhlenkamp & Co Inc added to a holding in Alerian MLP by 20.45%. The purchase prices were between $7.5 and $8.63, with an estimated average price of $8.09. The stock is now traded at around $7.72. The impact to a portfolio due to this purchase was 0.59%. The holding were 941,429 shares as of .

Muhlenkamp & Co Inc sold out a holding in Celgene Corp. The sale prices were between $97.62 and $110.41, with an estimated average price of $105.2.

Muhlenkamp & Co Inc sold out a holding in Corteva Inc. The sale prices were between $24.65 and $29.56, with an estimated average price of $26.49.

Muhlenkamp & Co Inc reduced to a holding in Gilead Sciences Inc by 70.23%. The sale prices were between $61.62 and $67.78, with an estimated average price of $65.21. The stock is now traded at around $67.00. The impact to a portfolio due to this sale was -2.88%. Muhlenkamp & Co Inc still held 39,475 shares as of .

Muhlenkamp & Co Inc reduced to a holding in Cognizant Technology Solutions Corp by 92.99%. The sale prices were between $58.9 and $64.15, with an estimated average price of $61.87. The stock is now traded at around $69.56. The impact to a portfolio due to this sale was -2.52%. Muhlenkamp & Co Inc still held 6,467 shares as of .

Muhlenkamp & Co Inc reduced to a holding in Cameco Corp by 55.01%. The sale prices were between $8.64 and $10, with an estimated average price of $9.24. The stock is now traded at around $9.07. The impact to a portfolio due to this sale was -2.15%. Muhlenkamp & Co Inc still held 380,132 shares as of .